Crohn's Disease

Crohn's Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fri, 03 Jun 2022 13:17:15 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease - Drugs In Development, 2022, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape.

Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Crohn's Disease (Gastrointestinal), complete with analysis ...

$2,500.00

KOL Perspectives: Histologic Healing in Crohn’s disease

Fri, 14 Dec 2018 12:46:34 +0000

Summary

This KOL Insight briefing focuses on KOLs views of Histologic Healing in Crohn’s disease.

Questions topics -
- Use of histological assessment in clinical trials and practice in Crohn’s disease
- Extrapolation of UC histology to UC
- Barriers to adoption of histology assessment in Crohn’s disease
- Impact of histological data in therapy choice in Crohn’s diseaseꟷViews on use of Geboes as an endpoint in Crohn’s disease
- Views on Phase II sub-analysis data for filgotinib

Key Highlights

- Majority of KOLs state that histologic healing is not used to assess Crohn’s disease patients in clinical practice
- Main barriers to adoption of histologic healing identified by KOLs include difficulty in accessing meaningful biopsy locations, as well as lack of data surrounding histology as a treatment goal
- Data showing moderate correlation between endoscopy and histology in Phase II does not impact on views of filgotinib efficacy.

Scope

- The insight briefing is based on Sociable Pharma’s analy...

$2,500.00

Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016’, provides an overview of the Crohn's Disease (Regional Enteritis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary d...

$2,000.00

Crohn’s disease (CD)- Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Crohn’s disease (CD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Crohn’s disease (CD) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Crohn’s disease (CD) till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Crohn’s disease (CD) market. • Identifying patient populations in the global “Crohn’s disease (CD)market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Crohn’s disease (CD) therapeutics in...

$4,950.00

Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2016

Sat, 28 May 2016 19:12:44 +0000

Summary

Global Markets Direct’s, ‘Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2016’, provides an overview of the Crohn’s Disease (Regional Enteritis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Crohn’s Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn’s Disease (Regional Enteritis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, co...

$2,000.00

Epiomic Epidemiology Series: Crohn's Disease Forecast in 8 Major Markets 2016-2026

Thu, 04 Feb 2016 12:47:18 +0000

Summary Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Crohn’s Disease in 8 Major Markets Crohn's disease, also known as regional enteritis, is a type of chronic inflammatory bowel disease. While it may affect any part of the gastrointestinal tract, it most commonly affects the ileus and colon. It is thought to be an auto-immune disease, although this theory has been challenged in recent years. This report provides the current prevalent population for Crohn’s disease across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Crohn’s have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also include...

$6,400.00